Pfizer, BioNTech Reach $1.95 Billion Coronavirus Vaccine Deal With US Government – By Marcy Kreiter (IB Times) / July 22 2020
- Pfizer and BioNTech are working on four vaccines, all based on mRNA
- Two of the Pfizer-BioNTech vaccine candidates have received fast-track status from the FDA
- Some 150 vaccine candidates are under development worldwide
Pfizer (PFE) and BioNTech (BNTX) reached agreement with the U.S. government Wednesday to produce 300 million doses of a COVID-19 vaccine in 2021. The agreement provides that a third of the production will go to the United States if the vaccine is approved by the Food and Drug Administration.
The FDA fast-tracked two of the four vaccines being developed by the two companies earlier this month after studies indicated they showed promise in boosting the immune system to fight off attempted infection by the coronavirus, which has affected nearly 15 million people worldwide, more than 3.9 million in the U.S. The agreement covers the vaccine labeled BNT162b1.
The $1.95 billion deal covers the first 100 million doses and provides for the U.S. to be able to acquire 500 million more doses.
Continue to article: https://www.ibtimes.com/pfizer-biontech-reach-195-billion-coronavirus-vaccine-deal-us-government-3015380
